|
|
Angiodynamics Inc (NASDAQ: ANGO) |
|
Price: $9.6000
$-0.04 
-0.415%
|
| Day's High:
| $9.73
| Week Perf:
| 5.38 %
|
| Day's Low: |
$ 9.48 |
30 Day Perf: |
-4.76 % |
| Volume (M): |
214 |
52 Wk High: |
$ 13.50 |
| Volume (M$): |
$ 2,052 |
52 Wk Avg: |
$8.03 |
| Open: |
$9.57 |
52 Wk Low: |
$5.47 |
|
|
| Market Capitalization (Millions $) |
392 |
| Shares
Outstanding (Millions) |
41 |
| Employees |
1,600 |
| Revenues (TTM) (Millions $) |
283 |
| Net Income (TTM) (Millions $) |
-41 |
| Cash Flow (TTM) (Millions $) |
-34 |
| Capital Exp. (TTM) (Millions $) |
8 |
Angiodynamics Inc
AngioDynamics Inc is a leading provider of innovative medical technologies and devices for minimally-invasive surgical procedures that are used in hospitals, clinics, and physician offices worldwide. The company's product portfolio includes medical devices that are designed to diagnose, treat, and manage a wide range of medical conditions, including peripheral vascular disease, cancer, and other serious medical conditions.
AngioDynamics was founded in Queensbury, New York, in 1988, and has since grown to become a global medical technology company. The company operates in more than 60 countries and employs over 1,400 people worldwide. The company's headquarters is located in Latham, New York.
The product portfolio of AngioDynamics includes a variety of medical devices and technologies that are used in interventional procedures including:
1. Peripheral Vascular Interventions: AngioDynamics offers a variety of products to diagnose and treat peripheral artery disease. These include the market-leading VenaCure EVLT laser system for treatment of varicose vein and the AngioVac cannula and circuit for extraction of clot in various vascular procedures.
2. Oncology: AngioDynamics provides a variety of technologies to diagnose and treat cancer, including the NanoKnife Irreversible Electroporation System, which uses electrical pulses to kill cancer cells.
3. Interventional Radiology: AngioDynamics' interventional radiology products include the BioFlo PICC, which is designed to reduce complications associated with central venous catheterization and the Bioflo Port, a power-injected, long-term use catheter.
4. Surgical Oncology: AngioDynamics offers a variety of products for surgical oncology, including radiofrequency ablation (RFA), microwave ablation, and cryoablation systems for the treatment of solid tumors.
In addition to its product portfolio, AngioDynamics also has a strong focus on research and development. The company invests a significant amount of resources in the development of new technologies and devices for minimally-invasive surgical procedures.
AngioDynamics has a strong reputation for quality and innovation, and its products are used by medical professionals across the globe. With its broad portfolio of medical technologies, AngioDynamics is well-positioned to continue growing and advancing the field of minimally-invasive surgical procedures.
Company Address: 14 Plaza Drive Latham 12110 NY
Company Phone Number: 795-1400 Stock Exchange / Ticker: NASDAQ ANGO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Tue, Dec 31 2024 1:30 PM UTC
AngioDynamics Triumphs: FDA Clears Innovative NanoKnife System for Prostate Treatment Amid Financial Prowess In a significant stride for medical innovation, AngioDynamics, Inc. (NASDAQ: ANGO), a dynamic player in the medical technology domain, has announced its recent achievement of the U.S. Food and Drug Administration (FDA) 510(k) clearance for their cutting-edge NanoKnife...
|
| Angiodynamics Inc
AngioDynamics Inc: Navigating Challenges and Pioneering New Frontiers in Medical TechnologyAs the financial landscape continues to evolve, one company that has recently drawn attention is AngioDynamics Inc. (NASDAQ: ANGO). The medical technology firm, based in Latham, New York, specializes in developing innovative solutions focused on restoring healthy blood flow, advancing cancer treatment options, and enhancing the quality of life for patients. However, financial results for the first quarter of fiscal year 2025 have revealed significant challenges that could impact investor sentiment moving forward. Financial Overview: Q1 of Fiscal Year 2025For the first quarter concluding August 31, 2024, AngioDynamics reported a net sales figure of $66.72 million, representing a notable decrease of 14.5% from $78.06 million in the same period last year. Additionally, sequentially, revenues decreased by nearly 8% from the preceding quarter's $72.52 million. This downturn in revenue, coupled with an extended net deficit of $-12.798 million?marking a stark contrast to a profit of $45.884 million reported a year prior?raises eyebrows among investors and analysts alike.
|
| Business Update
Published Fri, Sep 20 2024 12:47 AM UTC
Breaking Ground in Pulmonary Embolism Treatment: AngioDynamics Initiates Pioneering RECOVER-AV Clinical Trial Latham, N.Y. AngioDynamics, Inc. (NASDAQ: ANGO), a leading figure in transformative medical technology focused on vascular health, cancer treatment, and enhancing patient quality of life, has announced the initiation of the RECOVER-AV clinical trial. This groundbr...
|
| Business Update
Published Thu, Sep 19 2024 11:47 PM UTC
In the ever-evolving realm of medical technology, where innovation coalesces with the poignant demands of therapeutic efficacy, AngioDynamics, Inc., a venerable entity listed on the NASDAQ under the ticker ANGO, has recently taken a bold stride. This audacious initiative heralds the commencement of the RECOVER-AV clinical trial, primarily aimed at evaluating the AlphaVac F18...
|
| Business Update
Published Tue, Sep 3 2024 1:47 PM UTC
AngioDynamics, Inc., a prominent medical technology company renowned for its innovations in vascular health, announced on Monday that it has received CE Mark approval in Europe for its Auryon Atherectomy System. This system is particularly significant for the treatment of Peripheral Artery Disease (PAD), which affects millions of people worldwide, impairing blood flow to the...
|
| Per Share |
Current |
| Earnings (TTM) |
-1.01 $ |
| Revenues (TTM) |
6.93 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.1 $
|
| Book Value |
4.55 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.01 $
|
| Revenues (TTM) |
6.93 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.1 $
|
| Book Value |
4.55 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| United States |
|
 85.36 % |
of total Revenue |
| International |
|
14.84 % |
of total Revenue |
| Med Tech |
|
43.62 % |
of total Revenue |
| Med Tech United States |
|
37.57 % |
of total Revenue |
| Med Tech International |
|
6.04 % |
of total Revenue |
| Med Device |
|
56.59 % |
of total Revenue |
| Med Device United States |
|
47.79 % |
of total Revenue |
| Med Device International |
|
8.8 % |
of total Revenue |
|
|
6.09% 